ABVC — ABVC BIOPHARMA, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1173313 ·
Last close
$0.94
Market Cap
$25.36M
52W High
$2.96
52W Low
$0.71
ADV30
39,898
Next earnings
—
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 0 -779,526 -736,934 19,400,715 31,944 7,131,155
Mar 2026 0 0 -1,572,472 -1,560,242 19,732,528 140,324 6,904,071
Dec 2025 -795,950 -795,950 -2,994,861 -3,562,944 21,062,203 681,480 7,764,723
Sep 2025 0 0 -1,964,360 -2,042,463 21,176,299 192,068 6,683,592

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,522,401
Investing CF
$162,581
Financing CF
$2,237,393
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-79,155,537
Inventory
$11,460
Receivables
$165,806
ST Investments
$62,420
EBIT TTM
$-8,240,567
Pretax Income TTM
$-8,395,777
Interest Exp TTM
$155,210
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -7,151,259 -7,908,554 21,062,203 7,764,723 11,111,861 -2,986,299
Dec 2024 509,589 -4,705,242 -4,902,878 7,539,907 6,815,948 1,226,140 -1,809,145
Dec 2023 152,430 -6,766,734 -7,788,050 7,784,499 6,531,026 1,554,110 -4,186,848
Dec 2022 969,783 -15,114,412 -16,423,239 9,579,574 6,343,435 3,098,585 -7,398,391
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$133,341
NetIncome TTM
$-7,106,633
OpCashFlow TTM
—
Assets (Latest)
$19,400,715
Forward EPS
$-0.44

Peers — same industry

TickerNameMarket CapLastDaily %
BIOE Bio Essence Corp $25.29M $0.47 —
AARD Aardvark Therapeutics, Inc. $25.17M $1.15 —
CLCS Cell Source, Inc. $25.14M $0.37 —
BETRF BetterLife Pharma Inc. $25.64M $0.15 —
ACET Adicet Bio, Inc. $26.03M $2.78 —

News headlines (Yahoo Finance, 1h cache)

/C O R R E C T I O N - WallachBeth Capital LLC/
2026-11-02 15:00 · Yahoo
ABVC BioPharma Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of $3.39 Million
2026-11-02 14:30 · Yahoo
ABVC BioPharma, Inc. Announces Planned Spin-Off of BioKey (Cayman), Inc. Through Dividend Distribution of BioKey Shares to ABVC Shareholders
2026-06-23 12:30 · Yahoo
ABVC BioPharma Reports 2025 Form 10-K
2026-03-03 22:00 · Yahoo
ABVC BioPharma Provides Corporate and Structural Update
2026-02-24 13:30 · Yahoo
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States
2025-12-02 13:30 · Yahoo
ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook
2025-11-26 13:30 · Yahoo
ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received
2025-11-21 13:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.